Excess Adiposity Plays Role in Postmenopausal HR-Positive Breast Cancer
By Elana Gotkine HealthDay Reporter
THURSDAY, Oct. 17, 2024 -- Excess body fat plays a role in postmenopausal hormone receptor-positive breast cancer, which could be underestimated using only body mass index (BMI), according to a study published online Oct. 17 in the Journal of Epidemiology and Community Health.
Naiara Cubelos-Fernández, from the University of León Institute of Biomedicine in Spain, and colleagues conducted a case-control study of 1,033 breast cancer cases and 1,143 postmenopausal population controls to compare the burden of postmenopausal breast cancer attributable to excess body fat calculated using BMI and the Clínica Universidad de Navarra-Body Adiposity Estimator (CUN-BAE). Odds ratios were calculated and the population attributable fraction (PAF) of excess weight related to breast cancer was estimated for both measures.
The researchers found that excess body weight attributable to the risk for breast cancer was 23.0 and 38.0 percent when using a BMI value ≥30 kg/m2 and when using a CUN-BAE value of ≥40 percent body fat, respectively. These differences in PAFs were only seen in hormone receptor-positive cases, with an estimated burden of 19.9 and 41.9 percent for BMI and CUN-BAE, respectively.
"This information could influence cancer prevention initiatives by highlighting the role of excess body fat in the development of breast cancer and by raising awareness among health care professionals and the public," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Long-Term Obesity Linked to Expression of Aging Biomarkers
THURSDAY, July 17, 2025 -- Long-term obesity is associated with the expression of biomarkers denoting antagonistic and integrative aging hallmarks in adults aged 28 to 31 years...
ENDO: Older Age, Female Sex Tied to Greater Muscle Loss With Semaglutide
THURSDAY, July 17, 2025 -- Older age and female sex may be associated with greater muscle loss in adults with obesity prescribed semaglutide, and greater muscle loss is...
GLP-1 Receptor Agonist Use in T2D Tied to Increased Risk for GERD, GERD Complications
THURSDAY, July 17, 2025 -- For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with an increased risk for gastroesophageal...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.